Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
- 22 June 2009
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 162 (1), 74-79
- https://doi.org/10.1111/j.1365-2133.2009.09373.x
Abstract
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) represents the malignant counterpart derived from plasmacytoid dendritic cells. This rare entity is usually revealed and diagnosed on cutaneous lesions associated or not with a leukaemic component. The prognosis associated with BPDCN is very poor. Objectives To perform a retrospective review of BPDCN cases registered in the French Study Group on Cutaneous Lymphoma database from June 1995 to May 2008. Methods Forty-seven patients were included. Demographic data, initial staging, therapeutic management and outcome were recorded. Results The mean survival was 16·7 months (95% confidence interval 12·6–20·8). Only eight (17%) and one (2%) patients reached respectively 2 and 5 years of survival. Initial spreading of the disease did not represent, in this cohort, a reliable prognosis factor. The outcome was overall influenced by treatment provided. While radiation therapy, monochemotherapy or even polychemotherapy regimens did not significantly affect the course of the disease, the survival of bone marrow transplanted patients was significantly higher. Conclusions Despite the fact that BPDCN is often initially limited to the skin, only an aggressive initial therapy may improve the patients’ prognosis. Local treatments, such radiation therapy, are definitively useless. Regardless of the initial extension of the disease, in our experience only bone marrow transplantation significantly improved the outcome.This publication has 25 references indexed in Scilit:
- Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the diseaseLeukemia, 2009
- Antigen-Presentation Properties of Plasmacytoid Dendritic CellsImmunity, 2008
- Novel markers of normal and neoplastic human plasmacytoid dendritic cellsBlood, 2008
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- The ETS Transcription Factor Spi-B Is Required for Human Plasmacytoid Dendritic Cell DevelopmentThe Journal of Experimental Medicine, 2004
- Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 TrialJournal of Clinical Oncology, 2004
- In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory responseLeukemia, 2004
- The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell developmentBlood, 2003
- Subtractive hybridization reveals the expression of immunoglobulinlike transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cellsBlood, 2002
- Natural Interferon α/β–Producing Cells Link Innate and Adaptive ImmunityThe Journal of Experimental Medicine, 2000